© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
September 28, 2021
Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the University of Texas MD Anderson Cancer Center, discusses unmet clinical needs in myelofibrosis.
September 24, 2021
Add-on parsaclisib showed improvement in spleen volume and symptoms in patients with myelofibrosis who were having a suboptimal response to a stable dose of ruxolitinib.
September 22, 2021
Srdan Verstovsek, MD, PhD, discussed the future of myelofibrosis treatment, unmet clinical needs in this patient population, and new therapy options in an interview with Targeted Oncology™.
September 20, 2021
In an interview with Targeted Oncology™ during the SOHO Annual Meeting, Carole Miller, MD, discussed results from the REVEAL study and how the findings can be used to aid future research.
September 11, 2021
Despite the several classes of drugs either approved, or in development, for the treatment of myeloproliferative neoplasms, a big question remains.
September 10, 2021
Olatoyosi Sobulo Odenike, MD, explored the risk factors for evolution to MPN AP/blast phase, outcomes for current treatment methods, and potential targeted therapies during a presentation.
September 09, 2021
The JAK1/JAK2 inhibitor Ruxolitinib has numerous clinical uses for the treatment of polycythemia vera, especially for adult patients who have had an inadequate response to hydroxyurea.
In the REVEAL study, having high-risk polycythemia vera was associated with lower survival at 4 years compared with low-risk disease.
Active phase 2 and 3 studies offer different concepts to the treatment myelofibrosis, according to Srdan Verstovsek, MD.
Adapting therapy to patients using the available criteria may be the key to future treatment in patients with polycythemia vera.